-
-
-
-
-
-
-
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
-
-
-
-
-
-
-
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
-
-
-
-
-
-
1,197,452 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

